

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

17 Sep 2026

### Evaluation of the effect of high dose interlipid administration versus its gradual increase in neonates weighing less than 1500

#### Protocol summary

##### Study aim

study of the effect of high dose interlipid administration versus its gradual increase in preterm infants weighing less than 1500

##### Design

Study is randomized and patients were randomly divided into two parallel control and intervention groups (clinical trial). Randomization type is simple randomization and randomization unit were individual. Individuals were randomly divided into two groups of control and study.

##### Settings and conduct

Study is randomized, not blinded. 104 neonates born at Akbar abadi Hospital with very low birth weight (below 1500g) We divide into equal weight groups in weight groups and start with an injectable lipid emulsion from 1 g / kg per 24 hours and increase 1 gram daily to 3 grams per kilogram per 24 hours. In the other group, we will give a dose of 3 grams per kilogram from the beginning. Then, newborns are checked daily for blood glucose and weight. ABG is taken twice a week and triglycerides and CRP are performed. In cases of suspected sepsis, blood cultures are sent and we will monitor neonates until they are fed with milk up to 100 cc per kilogram of weight .

##### Participants/Inclusion and exclusion criteria

All neonates born in Akbar Abadi Hospital with a birth weight of less than 1500 grams who had no major anomalies and perinatal asphyxia (Apgar 5 minutes below 6) and had no sepsis. parents had a written consent for entry into the study. If parents are not willing to continue their studies or if there is any evidence of sepsis or metabolic acidosis, or high-triglyceride over 200 or glucose more than 200 three times or hypoxia less than 85% that treated with intralipid interruption, the study is finished and the baby is excluded from the study.

##### Intervention groups

104 neonates born at Akbarabadi Hospital with very low birth weight (below 1500g) We divide into equal weight groups in weight groups and start with an injectable lipid

emulsion from 1 g / kg per 24 hours and increase 1 gram daily to 3 grams per kilogram per 24 hours. In the other group, we will give a dose of 3 grams per kilogram from the beginning.

##### Main outcome variables

Effect of high dose interlipid administration versus its incremental to blood glucose and weighting and ABG and TG and CRP

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20160120026115N6**

Registration date: **2018-02-17, 1396/11/28**

Registration timing: **retrospective**

Last update: **2018-02-17, 1396/11/28**

Update count: **0**

##### Registration date

2018-02-17, 1396/11/28

##### Registrant information

##### Name

Mandana Kashaki

##### Name of organization / entity

Iran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 5563 2277

##### Email address

kashakimd@gmail.com

##### Recruitment status

##### Recruitment complete

##### Funding source

All costs are provided by the public sector (annual repayment of Iran University of Medical Sciences)

**Expected recruitment start date**

2016-03-20, 1395/01/01

**Expected recruitment end date**

2017-03-21, 1396/01/01

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the effect of high dose interalipid administration versus its gradual increase in neonates weighing less than 1500

**Public title**

Evaluation of the effect of high dose interalipid administration versus its gradual increase in neonates weighing less than 1500

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

All children born in Akbar Abadi Hospital with a birth weight of less than 1500 grams. Had no perinatal asphyxia (Apgar 5 minutes below 6). Parents had a written consent for entry into the study. Had no major anomalies.

**Exclusion criteria:**

If there is any evidence of sepsis before randomization If there is any evidence of metabolic acidosis before randomization hypoxia less than 90% before randomization

**Age**From **1 day** old to **28 days** old**Gender**

Both

**Phase**

N/A

**Groups that have been masked***No information***Sample size**Target sample size: **104****Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization type is simple randomization and randomization unit were individual. Individuals were randomly divided into two groups of control and study.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Iran University of Medical Sciences

**Street address**

Iran University of Medical Sciences, Hemmat Road, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1494868871

**Approval date**

2017-01-28, 1395/11/09

**Ethics committee reference number**

IR.IUMS.REC1395.9311165004

**Health conditions studied****1****Description of health condition studied**

advising of high doses interalipid

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Triglyceride

**Timepoint**

Before the intervention, then twice a week

**Method of measurement**

laboratory kit

**2****Description**

Arterial blood gas analysis and blood bicarbonate

**Timepoint**

Before the intervention, then twice a week

**Method of measurement**

laboratory kit

**3****Description**

Blood glucose

**Timepoint**

Before the intervention and then daily

**Method of measurement**

laboratory kit

#### 4

**Description**

neonate weight

**Timepoint**

Before the intervention and then daily

**Method of measurement**

Scales

#### 5

**Description**

CRP

**Timepoint**

Before the intervention, then twice a week

**Method of measurement**

laboratory kit

## Secondary outcomes

#### 1

**Description**

blood culture

**Timepoint**

Before intervention and then if symptoms of sepsis occur

**Method of measurement**

Observation of microbial growth in culture media

## Intervention groups

#### 1

**Description**

Control group: this group started with an injectable lipid emulsion from 1 gr / kg per 24 hours and increase 1 gram daily to 3 grams per kilogram per 24 hours . We monitor neonate with milk feeding until 100 cc / kg Or up to one month old (each one will arrive sooner).

**Category**

Treatment - Drugs

#### 2

**Description**

Intervention group: In the other group, initially, an interlipid dose of 3 grams per kilogram for 24 hours recommended.

**Category**

Treatment - Drugs

## Recruitment centers

#### 1

**Recruitment center****Name of recruitment center**

Akbar Abadi Hospital Tehran

**Full name of responsible person**

Mandana Kashaki

**Street address**

Akbar Abadi Hospital, Molav Ave

**City**

Tehran

**Province**

Tehran

**Postal code**

1494868871

**Phone**

+98 21 4474 0360

**Email**

kashakimd@gmail.com

## Sponsors / Funding sources

#### 1

**Sponsor****Name of organization / entity**

Vice chancellor for research of Iran University of Medical Sciences

**Full name of responsible person**

Leili Irani

**Street address**

Iran University of Medical Sciences, Hemmat highway

**City**

Tehran

**Province**

Tehran

**Postal code**

1494868871

**Phone**

+98 21 4474 0360

**Email**

kashakimd@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research of Iran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mandana Kashaki

**Position**

Assistant Professor

**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Pediatrics  
**Street address**  
hemmat high way, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1494868871  
**Phone**  
+98 21 5563 2277  
**Fax**  
+98 21 5563 2277  
**Email**  
kashakimd@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Akbar Abadi Hospital  
**Full name of responsible person**  
Mandana Kashaki  
**Position**  
Assistant Professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
**Street address**  
Shahid Akbar Abadi Hospital; molavi Ferdows Station;  
tehran  
**City**  
tehran  
**Province**  
Tehran  
**Postal code**  
1494868871  
**Phone**  
+98 21 5563 2277  
**Fax**  
**Email**  
kashakimd@gmail.com  
**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Iran University of Medical Sciences  
**Full name of responsible person**  
Babak Jafarvand  
**Position**  
Pediatric Resident  
**Latest degree**  
Medical doctor

**Other areas of specialty/work**  
Pediatrics  
**Street address**  
Shahid Akbar Abadi hospital, Ferdowsi Station, Molavi  
st.  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1494868871  
**Phone**  
+98 21 4474 0360  
**Fax**  
**Email**  
babakjafarvand1363@gmail.com  
**Web page address**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Yes - There is a plan to make this available

### Title and more details about the data/document

The total potential data can be shared after  
unidentifiable people.

### When the data will become available and for how long

The start of the access period is 6 months after the  
results are printed.

### To whom data/document is available

Data will only be available to researchers in academia.

### Under which criteria data/document could be used

Other conditions for the use of data or documentation  
are those who have been approved by scholars working  
in academic and scientific institutions.

### From where data/document is obtainable

Doctor Mandana Kashaki tel:09123580373  
kashakimd@gmail.com Doctor Babak Jafarvand  
tel:09122833963 babakjafarvand@gmail.com

### What processes are involved for a request to access data/document

The start of the access period is 6 months after the  
results are printed. Data will only be available to  
researchers in academia. Other conditions for the use of  
data or documentation are those who have been  
approved by scholars working in academic and scientific  
institutions.

### Comments